Q2 2024 Earnings Estimate for BridgeBio Pharma, Inc. Issued By HC Wainwright (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for shares of BridgeBio Pharma in a report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.99) per share for the quarter, down from their previous estimate of ($0.84). HC Wainwright currently has a “Buy” rating and a $43.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.20) per share. HC Wainwright also issued estimates for BridgeBio Pharma’s Q3 2024 earnings at ($1.00) EPS, Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($3.08) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.92) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.95) EPS and FY2025 earnings at ($3.72) EPS.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.35. The business had revenue of $211.12 million during the quarter, compared to analyst estimates of $140.06 million.

Other research analysts have also issued research reports about the stock. BMO Capital Markets assumed coverage on shares of BridgeBio Pharma in a research note on Wednesday, January 31st. They set a “market perform” rating and a $37.00 price target on the stock. Cantor Fitzgerald raised their target price on BridgeBio Pharma from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 19th. Citigroup lifted their price target on BridgeBio Pharma from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Mizuho cut their price objective on BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. lifted their target price on BridgeBio Pharma from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $47.67.

BridgeBio Pharma Stock Down 5.2 %

Shares of BridgeBio Pharma stock opened at $27.76 on Wednesday. The company has a 50 day moving average price of $27.93 and a 200 day moving average price of $32.07. The firm has a market capitalization of $5.19 billion, a P/E ratio of -8.62 and a beta of 1.08. BridgeBio Pharma has a 52 week low of $12.75 and a 52 week high of $44.32.

Insider Activity at BridgeBio Pharma

In related news, Director Randal W. Scott sold 2,500 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $34.00, for a total value of $85,000.00. Following the completion of the transaction, the director now directly owns 6,500 shares in the company, valued at approximately $221,000. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently modified their holdings of the business. YHB Investment Advisors Inc. acquired a new position in BridgeBio Pharma during the first quarter worth $34,000. Quarry LP acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth about $50,000. Assetmark Inc. lifted its stake in BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock valued at $118,000 after buying an additional 935 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in BridgeBio Pharma in the 1st quarter worth about $117,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in BridgeBio Pharma during the 3rd quarter worth approximately $132,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.